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Abstract
Introduction: Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease, and kidney
involvement with SLE, a.k.a. lupus nephritis (LN), is a frequent and severe complication of SLE that increases patient
morbidity and mortality. About 50% of patients with SLE encounter renal abnormalities which, if left untreated, can
lead to end-stage renal disease. Kidney biopsy is considered the criterion standard for diagnosis and staging of LN
using the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification, which was
developed to help predict renal outcomes and assist with medical decision-making. However, kidney biopsy-based
classification of LN is highly invasive and impractical for real-time monitoring of LN status. Here, nuclear magnetic
resonance (NMR) spectroscopy-based metabolic profiling was used to identify urinary metabolites that
discriminated between proliferative and pure membranous LN as defined by the ISN/RPS classification, and
between LN and primary focal segmental glomerulosclerosis (FSGS).
Methods: Metabolic profiling was conducted using urine samples of patients with proliferative LN without
membranous features (Class III/IV; n = 7) or pure membranous LN (Class V; n = 7). Patients with primary FSGS and
proteinuria (n = 10) served as disease controls. For each patient, demographic information and clinical data was
obtained and a random urine sample collected to measure NMR spectra. Data and sample collection for patients
with LN occurred around the time of kidney biopsy. Metabolic profiling analysis was done by visual inspection and
principal component analysis.
Results: Urinary citrate levels were 8-fold lower in Class V LN compared to Class III/IV patients, who had normal
levels of urinary citrate (P < 0.05). Class III/IV LN patients had > 10-fold lower levels of urinary taurine compared to
Class V patients, who had mostly normal levels (P < 0.01). Class V LN patients had normal urinary hippurate levels
compared to FSGS patients, who completely lacked urinary hippurate (P < 0.001).
Conclusions: This pilot study indicated differences in urinary metabolites between proliferative LN and pure
membranous LN patients, and between LN and FSGS patients. If confirmed in larger studies, these urine
metabolites may serve as biomarkers to help discriminate between different classes of LN, and between LN and
FSGS.
* Correspondence: kennedm4@muohio.edu
1Department of Chemistry and Biochemistry, Miami University, Oxford, OH
45056, USA
Full list of author information is available at the end of the article
Romick-Rosendale et al. Arthritis Research & Therapy 2011, 13:R199
http://arthritis-research.com/content/13/6/R199
© 2011 Romick-Rosendale et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Introduction
Systemic lupus erythematosus (SLE or lupus) is a
chronic autoimmune disease [1]. Kidney involvement
with SLE, a.k.a. lupus nephritis (LN), is a frequent and
severe complication of SLE that increases patient mor-
bidity and mortality [2]. About 50% of patients with SLE
encounter renal abnormalities which, if left untreated,
can lead to end-stage renal disease [3,4].
Kidney biopsy is considered the criterion standard for
diagnosis and staging of LN using the International
Society of Nephrology/Renal Pathology Society (ISN/
RPS) Classification [5]. This classification was developed
to help predict renal outcomes and assist with medical
decision-making. Treatment of patients diagnosed with
ISN/RPS class III or class IV LN requires combination
therapy with corticosteroids plus immunosuppressive
medications [6], whereas therapeutic choices for class V
LN are still under considerable debate [7]. The ISN/RPS
class of a patient with LN is not static. Over time, histo-
logical features of LN may improve in response to ther-
apy or degenerative changes can accrue. The lack of
sensitive and specific non-invasive biomarkers that assist
with distinguishing between various LN classes makes it
virtually impossible to dynamically monitor changes in
LN classes in real time. This impairs the timely initia-
tion of therapy and impairs monitoring of treatment
response.
It is particularly difficult to discriminate proliferative
LN (class III/IV) from pure membranous LN (class V)
clinically, as both are associated with pronounced pro-
teinuria, and changes in blood pressure and renal func-
tion. Pronounced proteinuria is also the hallmark of
primary focal segmental glomerulosclerosis (FSGS). One
of the histological characteristics of FSGS is podocyte
injury, which results in different degrees of proteinuria
and potentially, hypoalbuminemia, that is, these clinical
and histological features can also occur with active LN
[8].
In the past, we and others have used proteomics to
discover candidate protein biomarkers for LN [9,10].
Alternative biomarker discovery approaches include
metabolomics, that is, the systematic study of small-
molecule metabolite profiles or unique chemical finger-
prints that are the result of specific cellular processes,
and metabonomics, which can be defined as the quanti-
tative measurement of metabolite changes in such meta-
bolic profiles [11-13]. Nuclear magnetic resonance
(NMR) finger printing is currently the method of choice
for metabonomics because it provides uniform detection
of equal sensitivity for all proton-containing small mole-
cules and can provide valuable information on metabo-
lites directly from biofluids with little sample
preparation [14-16]. Metabonomics is achieved by
maximum data capture through NMR spectroscopy fol-
lowed by pattern recognition statistics [17].
The objective of this study was to identify urinary
metabolites that discriminated between proliferative LN
(class III/IV), pure membranous LN (class V), and
FSGS, using NMR spectroscopy-based metabonomics.
Metabolic profiles of urine samples were investigated
using high-field (850 MHz) solution-state NMR spectro-
scopy. Two urinary metabolites, citrate and taurine,
were found to accurately distinguish between class III/
IV and class V LN patients. Urinary citrate levels were
eight-fold lower than normal in class V compared with
class III/IV LN patients, who had normal levels of urin-
ary citrate. Also, class III/IV LN patients had more than
10-fold lower than normal levels of urinary taurine com-
pared with class V patients, who had mostly normal
levels of urinary taurine. Finally, urinary hippurate levels
accurately distinguished between class V patients, who
had normal levels of urinary taurine, in comparison with
FSGS patients, who completely lacked urinary hippurate.
Materials and methods
Patients and samples
All research was conducted in compliance with the Hel-
sinki Declaration. Informed consent was obtained from
all enrolled patients. The study was approved by the
institutional review boardso fb o t ht h eJ o h n sH o p k i n s
Hospital and the Cincinnati Children’s Hospital Medical
Center. Children and adults diagnosed with SLE [1] who
required a kidney biopsy as part of standard of care
therapy were eligible for inclusion in this study if a ran-
dom spot urine sample was available that was collected
within 60 days of the kidney biopsy. On the day of the
urine sample collection, information about patient
demographics, medications, and disease activity was col-
lected. Key laboratory measures were obtained, includ-
ing complement C3 and C4 levels, anti-dsDNA
antibodies (present/absent), amount of proteinuria as
estimated by the protein to creatinine ratio (P/C ratio)
in a random or 24-hour urine sample, serum creatinine,
and glomerular filtration rate (GFR) as estimated by
age-appropriate calculation of the creatinine clearance
[18,19]. For SLE patients to be included in the study,
they had to have undergone kidney biopsy, found to
have either class III or IV LN without membranous fea-
tures (class III/IV) or pure membranous class V LN as
per the ISN/RPS classification [5], had an available
stored urine sample collected within 60 days of a kidney
biopsy, and signed the informed consent form.
The histological characteristics of each kidney biopsy,
as per report from the local pathologists, were reviewed
in a blinded fashion by one expert nephropathologist, as
per the ISN/RPS classification [5]. The following histolo-
gical features reflective of active inflammation with LN
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karyorrhexis (also: fibrinoid necrosis); cellular crescents;
capillary proliferation, subendothelial deposits identifi-
able by light microscopy (also: wire-loops). We also
noted features representing LN chronicity or degenera-
tive damage. These included glomerular sclerosis (seg-
mental or global), fibrosis including fibrous adhesions
and fibrous crescents, as well as tubular atrophy. The
results of these classifications are summarized in supple-
mentary Table S1 [see Additional data file 1].
Almost all LN studies employ a previously developed
scoring system to quantify the amount of overall LN
activity and overall LN chronicity present in kidney
biopsy specimens [20]. The features of activity and
chronicity listed above were categorized as follows: 0
(no lesions), 1 (lesions in up to 25% of glomeruli), 2
(lesions in 25 to 50% of glomeruli) or 3 (lesions in >
50% of glomeruli). Using these numeric values, a Biopsy
Activity Index (AI) score (range 0 to 24) and a Biopsy
Chronicity Index (CI) score (range 0 to 12) can be cal-
culated, where higher scores represent higher LN activ-
ity or chronicity, respectively. The ISN/RPS
classification, the AI and the CI have all been validated
for use in adults and children with LN [21,22]. Risk fac-
tors for poor LN outcome include AI scores of seven or
higher and CI scores of four or higher [21,23-30]. The
AI and CI scores of the patients are also listed in sup-
plementary Table S1 [see Additional data file 1].
Epimembranous deposits, although not included in the
AI or the CI scores, were also recorded. Depending on
the findings of active inflammation, and chronic changes
observed on kidney biopsy, LN is classified in six cate-
gories. Pronounced predominance of epimembranous
deposits is compatible with class V of LN.
For patients with LN, key laboratory measures were
recorded, including complement C3 levels, anti-dsDNA
antibodies (present/absent), amount of proteinuria as
estimated by the P/C ratio in a random or 24-hour urine
sample, serum creatinine, and GFR as estimated by age-
appropriate calculation of the creatinine clearance
[18,19]. The renal domain score of the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI-R; range
0 to 16; 0 = inactive LN) served as the clinical measure of
LN activity [31]. The Systemic Lupus International Colla-
borating Clinics/American College of Rheumatology
Damage Index items addressing kidney damage (SDI-R;
range 0 to 3; 0 = no LN damage) were recorded as a clini-
cal measure of kidney damage with LN [32]. The results
of these laboratory measurements are summarized in
supplementary Table S2 [see Additional data file 1].
Ten patients with biopsy-proven primary FSGS and
proteinuria served as a disease control group. For con-
trols with FSGS, data and urine samples were collected
during visits to the pediatric nephrology clinics.
The demographics and kidney status of all patients
included in the study are summarized in Table 1.
Metabolic profiling
Preparation of urine samples for NMR analysis
Urine samples were stored at -80°C after collection and
thawed on ice prior to preparation for NMR analysis. A
1 ml aliquot of each sample was centrifuged for 10 min-
utes at 2655 × g, and then 350 μl of clear urine was
pipetted into a 1.5 ml microcentrifuge tube. A volume
of 350 ml of buffer (300 mM KH2PO4,2m MN a N 3,
0.2% trimethylsilyl propionate (TSP) in 20% D2O, pH
7.4) was added to each urine sample. A volume of 600
μl of the urine/buffer mixture was then pipetted into a 5
mm NMR tube (Norell ST500-7, Norell, Inc., Landis-
ville, NJ USA).
NMR data collection and processing
All NMR experiments were carried out on a Bruker
Avance™ III spectrometer (Bruker Biospin, Rheinstet-
ten, Germany) operating at 850.10 MHz
1H frequency
and equipped with a room temperature 5 mm triple
resonance probe with inverse detection and controlled
by TopSpin 2.1.4 (Bruker Biospin, Rheinstetten, Ger-
many). All experiments were conducted at 298 K. All
data were collected using a spectral width of 20.0 ppm.
Three
1H NMR experiments, optimized by Bruker (Bru-
ker BioSpin, Billerica, MA, USA) for use with metabo-
nomic studies, were run on all samples: a standard 1D
presaturation (zgpr), a 1D first increment of a nuclear
Overhauser effect spectroscopy (NOESY; noesygppr1d)
experiment, and a CPMG (cpmgpr1d) experiment. All
experiments included presaturation of the water peak.
The transmitter offset frequency (O1) was set to
4002.80 Hz to obtain optimal water suppression. The
90° pulse width was determined for every sample using
the automatic pulse calculation feature in TopSpin. All
pulse widths were between 13 and 16 μs. Water sup-
pression was achieved by irradiation of the water peak
during a recycle delay of 4.0s with a pulse power level
of 55.92 dB.
One-dimensional zgpr
1H NMR spectra were acquired
using two transients and two dummy scans, 65 K points
per spectrum giving an acquisition time of 1.92 s, -0.01
Hz of exponential line broadening, and a recycle delay
of 4 seconds. Once the zgpr spectrum was determined
to be of acceptable quality, based on the line width (< 1
Hz) and line shape (resolved C13 satellites) of the TSP
internal standard, the other two experiments were run.
The first increment of the 1D NOESY experiment was
collected using eight transients with four dummy scans,
65 K points per spectrum giving an acquisition time of
1.92 seconds, a mixing time of 10 ms, and apodized
using a Gaussian line broadening parameter of 0.01, and
a 4 seconds recycle delay. The CPMG experiment was
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in the spectrum. The CPMG experiment used 64 transi-
ents with four dummy scans, 65 K points per spectrum
giving an acquisition time of 1.87 seconds, a T2 filter
loop of 128 with an echo time of 1 ms, apodized using
-0.01 Hz of exponential line broadening, and a 4 sec-
onds recycle delay.
All NMR spectra were phased, baseline corrected, and
corrected for chemical shift registration relative to TSP
in TopSpin 2.1.1 (Bruker Biospin, Billerica, MA, USA).
Box and whisker plot analysis
Box and whisker plots were generated in excel using a
template provided by Vertex42 LLC
Principal component analysis
The data were subjected to multivariate statistical analy-
sis using AMIX software version 3.9.7 (Bruker Biospin,
Billerica, MA, USA). All NMR spectra were normalized
to total intensity prior to principal component analysis
(PCA). NMR spectra were binned into 0.03 ppm-wide
buckets, using simple rectangular bucketing, over the
region of δ10.0 to 0.2 ppm. The region of δ 4.75 to 5.0
was excluded from the analysis to avoid effects of
imperfect water suppression. Buckets with variances less
than 5% were also excluded from PCA.
Unsupervised PCA was performed without considera-
tion of group information (class III/IV; class V, FSGS).
The algorithm employed to calculate the principal com-
ponents (PC) is discussed by Rousseau et al. [33]. As is
commonly done with metabolomic data, visualization of
the data was accomplished by inspection of the PC
scores plots and loadings plots.
Statistical significance analysis of NMR data
Statistical significance analysis was performed for the
comparison of class III/IV and class V LN, as well as the
comparison of class V LN and FSGS, using AMIX 3.9.7
(Bruker Biospin, Rheinstetten, Germany), as outlined by
Goodpaster et al. [34]. A critical value of alpha of 0.05
was selected to ensure no greater than a 5% false positive
rate. In order to correct for multiple simultaneous test-
ing, a Bonferroni correction was applied to the critical
value to ensure a constant family-wise false positive rate
[34]. The Bonferroni corrected critical value was calcu-
lated by dividing alpha by the number of buckets used in
the PCA, resulting in a stringent P value threshold for
determination of statistically significant changes in reso-
nance intensities between groups being compared. The
number of buckets used for statistical significance analy-
sis was determined by the number remaining after omit-
ting buckets that contained less than 5% variance and
after omitting buckets in the excluded regions. A change
in bucket intensity between groups was determined to be
statistically significant if its P value was less than the
Bonferroni corrected critical value.
Mahalanobis distance and F-value calculations
Mahalanobis distance calculations and F-value calcula-
tions were performed in MatLab as described by Good-
paster et al. [35]. Critical F-values were calculated using
a critical F-value calculator [36].
Table 1 Patient demographics, medications and renal status at the time of the urine collection.
Focal segmental
glomerulosclerosis
Proliferative LN
(class III or IV)
Pure membranous LN
(class V)
no f1 0
(%)
Median
(Range)
no f7
(%)
Median
(Range)
n of 7 (%) Median
(Range)
Females 3 (33%) 4/7 (57%) 5/7 (71%)
Race Black 2/10 (20%) 3/7 (42%) 3/7 (42%)
White 5/10 (50%) 2/7 (29%) 2/7 (29%)
Other 3/10 (30%)* 2/7
(29%)†
3/7 (43%)
**
Medications Oral prednisone 4/10 (40%) 7/7
(100%)
4/7 (57%)
Mycophenolate mofetil 5/10 (50%) 3/7 (43%) 5/7 (71%)
Cyclophosphamide - 2/7 (29%) 1/7 (14%)
Angiotensin blocking agent 9/10 (90%) 2/7 (29%) 6/7 (86%)
Kidney
Status
GFR < 60 ml/min/m
2 4/10 (40%) 1/7 (14%) 1/7 (14%)
Protein: creatinine ratio > 0.5 5/5 (100%) 7/7
(100%)
7/7 (100%)
Renal SDI score > 0¥ - 0/3 1/4 (25%)
Renal SLEDAI score
‡ - 4 (0-16) 8 (4-12)
Presence of anti double-stranded-
dsDNA
- 7/7
(100%)
4/7 (67%)
‡ Systemic Lupus Erythematosus Disease activity Index (SLEDAI) - renal component score; ¥ Systemic Lupus International Collaborating Clinics/American College
of Rheumatology Damage Index - renal component score; *American Indian 1, Asian 1, Mixed racial 1; † Asian 1, Mixed racial 1; ** Asian 1, Unknown
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Experimental NMR spectra obtained from study samples
were compared with spectra of known metabolites using
the ChenomX NMR Suite (ChenomX Inc., Edmonton,
Alberta, Canada). The ChenomX database was used to
filter for resonance frequencies at chemical shifts corre-
sponding to those identified as outliers by visual com-
p a r i s o na sw e l la si nt h el o a d ings plot. Spectra present
in the ChenomX database were examined to verify if the
pattern of peaks matched those observed in the experi-
mental data.
Results and discussion
Patients
A total of seven patients with proliferative LN without
membranous features (class III/IV), seven patients with
pure membranous LN (class V), and 10 disease controls
with primary FSGS were included in the study.
NMR metabonomics data analysis
Due to slight variations in the pH of the urine samples,
the NMR peaks of some metabolites experienced pH-
dependent chemical shifts, making it difficult to identify
variances for these peaks by PCA using standard rectan-
gular bucketing. Therefore, all spectra were also visually
inspected to validate NMR resonances that were poten-
tially changing between groups, and then these peaks
were locally aligned to enable reliable P score
calculations.
Visual inspection of the NMR spectra of class III/IV
and class V LN patients led to the identification of one
metabolite, citrate, that had an eight-fold higher urinary
concentration (Table 2) (P score = 0.0477) in class III/
IV LN patients (1.11 ± 0.97 mM) compared with class V
patients (0.14 ± 0.15 mM). The concentration of citrate
in the class III/IV group fell into the normal range in
human urine [37] whereas the citrate levels in the class
V group were at the lower limit of published values
[37]. A receiver operator characteristic (ROC) analysis
indicated the citrate had 100% specificity at 86% sensi-
tivity and an overall 88% accuracy [see Additional data
file 1] for distinguishing between class III/IV and class
V LN patients. Urinary citrate levels were also compared
with the SLEDAI-R, CI, and P/C ratio (Figure 1). The
comparisons shown in Figure 1 further indicated that
there was a strong correlation between disease class and
citrate levels; however, no correlation was observed
between class and SLEDAI, CI, or P/C ratio between
class III/IV and class V LN patients. Complete summa-
ries of measured patient indices, including others not
presented in Figure 1, are presented in Tables S1 and S2
of the Supplementary Material.
Visual comparison of the NMR spectra of urine sam-
ples of patients with class III/IV versus class V LN also
Table 2 Concentrations and fold-changes of urinary
metabolites measured in Class III/IV, Class V LN and FSGS
patients.
Citrate Class IV (mM) Class V (mM) Fold change
0.59 0.15
2.16 0.32
2.68 0
0.85 0.36
1.15 0.055
00
0.37 0.083
ave (std) 1.11 (0.97) 0.14 (0.15) 8.04
Taurine Class IV (mM) Class V (mM) Fold change
0 1.84
0 7.51
0 2.32
0 0.32
0 2.61
0 0.85
0 0.55
ave (std) 0 2.29 (2.47) > 10
Hippurate Class V FSGS (mM) Fold change
1.79 0
0.70 0
0.55 0
0.47 0
1.49 0
1.66 0
1.89 0
0
0
0
ave (std) 1.22 (0.62) 0 > 10
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Citrate 
Concentration 
(mM) 
Taurine 
Concentration 
(mM) 
Renal SLEDAI  Chronicity  Protein: 
Creatinine 
Ratio 
Citrate 
Concentration 
(mM) 
Taurine 
Concentration 
(mM) 
Renal SLEDAI  Chronicity  Protein: 
Creatinine 
Ratio 
Class III/IV                                                         Class V 
Figure 1 Box and whisker plots. The plots shown are comparing
citrate concentration (mM), taurine concentration (mM), SLE Disease
Activity Index (SLEDAI), chronicity index (CI), and urine creatinine
(mg/mL) for class III/IV versus class V LN patients.
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class V LN (2.29 ± 2.47 mM) compared with class III/
IV LN patients, which lacked taurine altogether (Table
2) (P score = 0.00141). Taurine is normally present
urine at levels in the range from 50 to 750 μM[ 3 8 ] .
Therefore, the complete absence of taurine in class III/
IV patients indicated a renal pathology that was distinct
from class V patients who appeared to have mostly nor-
mal levels of taurine, with the exception of one patient
who had more than five times the normal amount of
taurine in the urine (Table 2). Discrimination of the two
groups (class III/IV versus class V) based on urinary
taurine levels was confirmed by PCA by restricting the
spectral analysis just to the region of the
1H NMR spec-
tra that contained the taurine-specific triplet at δ 3.425
ppm (Figure 2). Inspection of the PC scores plot of
these samples showed a significant separation of the
class III/IV from the class V populations, primarily
based on higher levels of taurine in the urine of patients
with class V LN (Figure 2a). The magnitude of the clus-
ter separation was quantified by calculating the Mahala-
nobis distance between the cluster centroids and the
statistical significance of the cluster separation was eval-
uated by calculating the F-value and comparing it with
the critical F-value (Figure 2a). The Mahalanobis dis-
tance of 2.282 between class III/IV and class V LN
group centroids and the corresponding F-value of 8.353
(critical F-value 3.982) indicated a statistically significant
separation of the two groups. The PC loadings plot cor-
responding to the PC scores plot shown in Figure 2a is
shown in Figure 2b. The difference in the mean intensi-
ties of the bucket at δ 3.425 ppm, which corresponded
to taurine, was found to be statistically significant with a
P value of 0.00151.
ROC curve analysis indicated that taurine was a per-
fect predictor for discrimination between class III/IV
and class V LN patients with 100% specificity, 100% sen-
sitivity and 100% accuracy [see Additional data file 1].
Urinary taurine levels were also compared to SLEDAI,
CI, and P/C ratio (Figure 1). As indicated above, the
data failed to reveal any correlation between LN class
and SLEDAI, CI, or urinary P/C ratios; however, a
strong correlation between class III/IV and class V LN
and was observed with a complete absence of urinary
taurine in class III/IV patients compared with mostly
normal levels of taurine in class V patients.
Unsupervised PCA was also carried out on normal-
ized
1H NMR spectra obtained from urine samples
from Class V LN and FSGS patients. Inspection of the
PC scores plot showed separation of the class V from
the FSGS group based on the levels of hippurate,
which were in the normal range found in human urine
[37] in the class V LN group (1.22 ± 0.62 mM), com-
pared with the FSGS group, which completely lacked
hippurate (Figure 3a; Table 2). The Mahalanobis dis-
tance between the cluster centroids of the class V and
FSGS groups was 1.781, with a corresponding F-value
of 6.096 (critical F-value 3.739) indicating a statistically
significant separation of these groups. NMR spectra of
patients with class V LN or FSGS were visually com-
pared to validate the differences in hippurate concen-
trations indicated by PCA. Figure 4 shows a region of
Figure 2 Principal component analysis of urine samples from
patients with class III/IV LN and class V LN. (a) Two-dimensional
principal component analysis scores plot of urine samples from
patients with class III/IV LN (green) and class V LN (black) for peaks
in the region from δ 3.40 to 4.50 ppm calculated using the first two
principal components. Each point in the scores plot represents the
NMR spectrum of an individual patient projected onto the two-
dimensional space defined by the first two principal components.
The dashed lines encircling the points define the 95% confidence
intervals for each group. The color-matched stars indicate the
centroid of each group and the line connecting the stars represents
the Mahalanobis distance between the group centroids. (b) The
loadings plot corresponding to the scores plot shown in Figure 1a.
The labeled bucket (point) corresponds to the triplet belonging to
taurine in the
1H NMR spectra. The coordinates of each point
indicate the PC loadings for that bucket, and represent how
strongly that bucket is weighted in the eigenvector defining either
the first or second principal component. The loadings plot points
are heat map color-coded according to bucket P value: Black (>
1.25 × 10
-2), Blue (1.25 × 10
-2-10
-5). The Bonferroni corrected a-value
was 0.0125.
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hippurate located at δ 7.64 and δ 7.55 ppm confirming
that hippurate was present in the class V group but
completely absent in the FSGS group. The differences
in the mean bucket intensities at δ 7.55 ppm and δ
7.64 between the two groups (> 10-fold change) were
found to be significant: δ 7.55 P value = 0.000171, and
δ 7.64 P value = 0.000379, respectively. ROC curve
analysis indicated that hippurate was a perfect discri-
minator for distinguishing between class V LN and
FSGS patients with 100% specificity, 100% sensitivity,
and 100% accuracy [see Additional data file 1]. Inter-
estingly, the complete lack of hippurate in the FSGS
group indicated a unique pathology in FSGS compared
with LN that leads to depletion of the normal urinary
levels of hippurate.
Kidney biopsies are currently required to distinguish
between different classes of LN, and between LN and
other glomerular disorders, based on characteristic his-
tological features. Obtaining kidney biopsies is invasive,
and repetitive performance to guide day-to-day medical
decisions is not practical. Although diagnostic, kidney
biopsies are not suited to pinpoint altered metabolic
processes or biological pathways involved in LN, which
if detected, could lead to the identification of novel ther-
apeutic targets. As the kidneys filter and reabsorb meta-
bolites to maintain a metabolic equilibrium, existence of
renal pathologies can impair the filtration of small meta-
bolites through the glomerulus and their subsequent re-
absorption in the renal tubules leading to changes in
metabolic profiles [39]. Using NMR-spectroscopy, we
found the metabolites taurine, citrate, and hippurate dif-
ferentially excreted in the urine of patients with prolif-
erative LN, membranous LN, and FSGS.
Comparison of the metabolic profiles of class III/IV
LN versus class V LN patients indicated that class III/IV
patients had normal urinary citrate levels but low urin-
ary taurine levels whereas class V LN patients exhibited
low urinary citrate levels but elevated urinary taurine
levels. Based on previous reports, citrate and taurine are
both measures of tubular cell function [40]. A possible
explanation for the reduced excretion of urinary citrate
in the class V LN group could be the presence of meta-
bolic acidosis, which is known to cause decreased urin-
ary excretion of citrate in humans [41]. It is believed
that patients experiencing low urinary citrate output
may have renal tubular cells that are more acidotic than
in the healthy normal populations [42]. The proximal
Figure 3 Principal component analysis of urine samples from
class V LN patients and focal segmental glomerulosclerosis
patients. (a) Two-dimensional principal component analysis scores
plot of urine samples from patients with class V LN patients (black)
and focal segmental glomerulosclerosis patients (red) using the first
two principal components. The dashed lines encircling the points
define the 95% confidence intervals for each group. The color-
matched stars indicate the centroid of each group and the line
connecting the stars represents the Mahalanobis distance between
the group centroids. (b) The loadings plot corresponding to the
scores plot in Figure 2a. The buckets shown are in the region from
δ 0.02 to 10.0 ppm. The loadings plot is heat map color-coded
according to bucket P values: Black (> 1.730 × 10
-4), Blue 1.730 ×
10
-4-10
-5). The Bonferroni corrected a-value was 1.730 × 10
-4.
Figure 4 NMR urine spectra in the region from 7.650 to 7.550
ppm of class V LN patients (black) and focal segmental
glomerulosclerosis patients (red). The triplets at δ7.64 and δ7.55
belong to the metabolite hippurate, as indicated in the inset.
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tion and excretion of citrate [43,44]. The body’s
response to metabolic acidosis includes an increase of
sodium/citrate co-transporter activity in the kidney,
which causes increased citrate transport across the api-
cal membrane into the tubule lumen [44]. Up-regulation
of the co-transporter activity results in the increased re-
absorption of citrate and reduced excretion of the meta-
bolite into the urine. The cytosolic citrate metabolism
also plays a key role in regulating the amount of citrate
excreted into the urine. During metabolic acidosis,
alterations in the enzyme ATP citrate lyase also results
in decreased urinary citrate excretion [44].
Class III/IV LN patients had a striking absence of
urinary taurine. Although the pathology leading to a
complete absence of urinary taurine is not obvious, the
body’s store of taurine is known to be regulated by the
kidneys and taurine is known to act as an anti-oxidant
in a variety of in vitro and in vivo systems, and is used
to treat renal dysfunction [45]. Therefore, it is possible
that under the conditions of the most severe LN in class
III/IV patients the kidneys utilize all available taurine in
an attempt to manage or repair the kidney pathology.
Although the majority of patients with class V LN
have normal levels of taurine, one patient had more
than five times the normal amount of taurine. A possi-
ble explanation for the elevated level of taurine in the
urine of this exceptional class V LN patient may be a
consequence of inadequate re-uptake of taurine into the
cells [46]. Taurine is excreted through both bile and
urine, but its total body pool is primarily controlled by
the kidneys via the renal tubules [47]. Previous studies
suggest that tubular dysfunction is a risk factor of taur-
ine deficiency [48]. Patients in renal failure often have
low muscle and plasma concentrations of taurine.
Although it has been suggested in the past that this was
due to reduced taurine synthesis [48], our results sug-
gest that low taurine levels are actually the result of
increased urinary taurine excretion.
Increased urinary taurine may also be a result of changes
in cysteine metabolism. Hypercysteinemia is associated
with alterations of the sulfur metabolism and/or sulfate
transport [49]. Taurine is known to play a critical role in
these processes [49], and patients with class V LN may be
unable to adequately cope with oxidative stress and the
elimination of free radicals. Interestingly, based on animal
studies, the acquisition of age-related renal fibrosis can be
decreased by taurine supplementation [50], and taurine
also has anti-hypertensive effects [51].
Histological scoring and quantification of proteinuria
are key methods used to survey disease activity and
severity in patients with LN [52,53]. Pirani et al. created
a scoring system that is semi-quantitative [54], which
was later adapted by Austin et al. [20] This system was
developed to calculate the activity of LN (SLEDAI) by
assessing six histological factors focusing on the severity
of active lesions in the glomeruli, and the chronicity of
the disease by evaluating four histological parameters
focusing on the reversibility of LN [53]. Wallace et al.
provides a table (Table 55-5 in the original article) that
outlines the scoring strategies for both the AI and CI
[55]. The degree of proteinuria is determined by mea-
suring the P/C ratio in a 24-hour urine collection. This
ratio has previously proven to be a reliable predictor of
proteinuria in a study of LN patients [56]. The changes
in citrate and taurine levels in the patients included in
this study were plotted against the SLEDAI, CI, and P/C
ratios in order to determine whether a correlation
existed between any of these conventionally measured
indices and biopsy-determined LN class (Figure 1). The
data showed that no clear correlation existed between
these conventional indices or P/C ratios and the LN
class; however, our data indicated strong correlations
between citrate and taurine levels and LN class. The
lack of correlation between renal activity and chronicity
with disease class is not surprising given that other stu-
dies have shown that when applying these indices to all
World Health Organization classes of LN, rather than
just diffuse proliferative LN, these indices lack an asso-
ciation with long-term prognosis [57,58]. The inability
to relate P/C ratio to disease class is also expected
because differing degrees of proteinuria are present
throughout the patient population. Visual comparison of
the above indices as they related to LN class further
demonstrated a strong need for continued development
of reliable biomarkers that allow for LN class differentia-
tion, as was seen in the changes in the metabolites iden-
tified in this study.
Our pilot study also identified one urinary metabolite,
hippurate, whose levels differentiated class V LN and
FSGS patients. Specifically, class V LN patients had nor-
mal levels of urinary hippurate whereas FSGS patients
completely lacked hippurate. Although the pathological
link associated with a complete lack of urinary hippurate
is not evident, the complete lack of urinary hippurate in
FSGS patients is striking. A possible pathological cause
could be related to having a distinct gut microbial biota,
which has been linked to depleted excretion of hippu-
rate in patients with Crohn’s disease [59].
Conclusions
Currently, it is difficult to distinguish between class III/
IV and class V LN, and FSGS using conventionally mea-
sured indices. Diagnoses require invasive and time-con-
suming procedures involving biopsies and histological
analyses, which make monitoring of real-time changes
in the disease pathology impossible using current tech-
nologies. Ideally, one would like to develop a non-
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Page 8 of 10invasive and rapid biomarker-based methodology to dis-
tinguish between class III/IV and class V LN, and FSGS.
Here we report putative urinary biomarkers for this pur-
pose obtained from a pilot study. Using NMR spectro-
scopy, we found that the metabolites taurine, citrate,
and hippurate were differentially excreted in the urine
of patients with proliferative LN, membranous LN, and
FSGS. Not only do these metabolites represent potential
biomarkers for distinguishing classes of LN and FSGS,
but consideration of the metabolic pathways involving
these metabolites should lead to a better understanding
of the pathology of the respective disease states.
Although the small size of this pilot study limits its sta-
tistical power, it is in the realm of similar pilot studies
for other diseases [60]. Nonetheless, our study has gen-
erated several hypotheses regarding the etiology of LN
and FSGS and further validation of our findings is
planned using an independent cohort of patients.
Additional material
Additional file 1: There are two additional tables included in this
file, including Table S1, which provides a summary of classifications
from histological analyses of kidney biopsy samples, and Table S2,
which is a summary of laboratory test scores for LN patients. The
file also contains Figure S1, which includes the receiver operator
characteristic curves for citrate, hippurate and taurine.
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